Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5383054 | 0.99 | SIGMAR1 (0.48) | SIGMAR1HTR1AOPRM1OPRL1HRH3 | |
| SCHEMBL5582639 | 0.86 | SIGMAR1 (0.45) | SIGMAR1HTR1AOPRM1OPRL1HRH3 | |
| SCHEMBL4621851 | 0.83 | CYP19A1 (0.52) | SIGMAR1HTR1AOPRM1OPRL1HRH3 | |
| Hydrochloric Acid SCHEMBL4622114 | 0.82 | CYP19A1 (0.51) | SIGMAR1HTR1AOPRM1OPRL1HRH3 | |
| SCHEMBL5904201 | 0.81 | CYP19A1 (0.53) | SIGMAR1HTR1AOPRM1OPRL1HRH3 | |
| SCHEMBL14454747 | 0.80 | SIGMAR1 (0.68) | SIGMAR1HTR1AOPRM1OPRL1MCHR1 | |
| Bromide SCHEMBL5904342 | 0.80 | CYP19A1 (0.52) | SIGMAR1HTR1AOPRM1OPRL1HRH3 | |
| Hydrochloric Acid SCHEMBL4622628 | 0.79 | SIGMAR1 (0.68) | SIGMAR1HTR1AHRH3HRH1MCHR1 | |
| SCHEMBL7254813 | 0.79 | SIGMAR1 (0.40) | SIGMAR1HTR1AOPRM1OPRL1MCHR1 | |
| SCHEMBL14454746 | 0.79 | SIGMAR1 (0.70) | SIGMAR1HTR1AOPRM1OPRL1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
| EP-1218336-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021577-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | SIGMAR1 72/4885HTR1A 73/4885OPRM1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.